TY - JOUR
T1 - Repurposing infectious disease vaccines for intratumoral immunotherapy
AU - Melero, Ignacio
AU - Gato, Maria
AU - Shekarian, Tala
AU - Azna, Angela
AU - Valsesia-Wittmann, Sandrine
AU - Caux, Christophe
AU - Etxeberrria, Inaki
AU - Teijeira, Alvaro
AU - Marabelle, Aurelien
N1 - Publisher Copyright:
© 2020 Author(s) (or their employer(s)). Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020/2/25
Y1 - 2020/2/25
N2 - Intratumoral delivery of viruses and virus-associated molecular patterns can achieve antitumor effects that are largely mediated by the elicitation or potentiation of immune responses against the malignancy. Attenuated vaccines are approved and marketed as good manufactiring practice (GMP)-manufactured agents whose administration might be able to induce such effects. Recent reports in mouse transplantable tumor models indicate that the rotavirus, influenza and yellow fever vaccines can be especially suitable to elicit powerful antitumor immunity against cancer following intratumoral administration. These results highlight that intratumoral anti-infectious vaccines can turn cold tumors into hot, and underscore the key role played by virus-induced type I interferon pathways to overcome resistance to immune checkpoint-targeted antibodies.
AB - Intratumoral delivery of viruses and virus-associated molecular patterns can achieve antitumor effects that are largely mediated by the elicitation or potentiation of immune responses against the malignancy. Attenuated vaccines are approved and marketed as good manufactiring practice (GMP)-manufactured agents whose administration might be able to induce such effects. Recent reports in mouse transplantable tumor models indicate that the rotavirus, influenza and yellow fever vaccines can be especially suitable to elicit powerful antitumor immunity against cancer following intratumoral administration. These results highlight that intratumoral anti-infectious vaccines can turn cold tumors into hot, and underscore the key role played by virus-induced type I interferon pathways to overcome resistance to immune checkpoint-targeted antibodies.
UR - http://www.scopus.com/inward/record.url?scp=85080137997&partnerID=8YFLogxK
U2 - 10.1136/jitc-2019-000443
DO - 10.1136/jitc-2019-000443
M3 - Article
C2 - 32102830
AN - SCOPUS:85080137997
SN - 2051-1426
VL - 8
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 1
M1 - e000443
ER -